Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics
Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies